NCT07098104Completed
A Benefit Population Atlas of nICT Versus nCT for LAGC
Identifying Optimal Responders: A Benefit Population Atlas of Neoadjuvant Immunochemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer
Source: ClinicalTrials.gov · Last updated 1 Aug 2025
Brief summary (registry, in English)
The purpose of this observational study is to evaluate the impact of different neoadjuvant therapies on patients with locally advanced gastric cancer. The primary question it aims to address is: Which patient populations benefit most from neoadjuvant immunochemotherapy versus neoadjuvant chemotherapy in locally advanced gastric cancer?
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 291 (actual)
- First submitted
- 27 Jul 2025
- Start date
- Nov 2019
- Primary completion date
- Dec 2023
- Lead sponsor
- Cheng Chen
- NCT number
- NCT07098104
What you commit to
- Study type: Observational
- Participants enrolled: 291
- From Nov 2019 to the primary completion date, Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Eligible patients had pathologically confirmed adenocarcinoma, imaging-confirmed resectable LAGC (cT2-4aN0-3M0, AJCC 8th), no distant metastases, and completed protocol-specified neoadjuvant therapy (nICT: PD-1/PD-L1 inhibitors plus two-drug chemotherapy; nCT: two-drug \[SOX/XELOX\] or three-drug \[FLOT/DCF\] chemotherapy) with ECOG 0-1.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jiangsu Cancer Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.